Potassium Monitoring and Management with Torsemide

Baseline Assessment

The Mayo Clinic recommends checking serum potassium before initiating torsemide and tailoring monitoring to patient risk factors such as chronic kidney disease, heart‑failure severity, concurrent RAAS‑inhibitor therapy, and baseline renal function. 1

Monitoring frequency should be intensified for patients receiving concurrent RAAS inhibitors, those with an estimated glomerular filtration rate < 60 mL/min/1.73 m², or those with a prior history of hyperkalemia, to ensure timely detection of electrolyte disturbances. 1
The Mayo Clinic emphasizes that the potassium‑sparing effect of torsemide does not eliminate the need for electrolyte surveillance in high‑risk groups, including advanced chronic kidney disease, concurrent RAAS‑inhibitor use, and diabetes. 1

In patients with stage 4–5 chronic kidney disease, a broader acceptable serum potassium range of 3.3–5.5 mEq/L is recommended, compared with a range of 3.5–5.0 mEq/L for individuals with normal renal function. 1

The American College of Cardiology advises that loop diuretics for heart failure should always be combined with guideline‑directed medical therapy—including RAAS inhibitors and mineralocorticoid receptor antagonists—because these agents influence potassium balance. 2
If hypokalemia develops while on torsemide, the American College of Cardiology recommends adding a potassium‑sparing diuretic such as spironolactone rather than discontinuing torsemide, aligning with heart‑failure GDMT that incorporates MRAs. 2
The American College of Cardiology suggests reserving the addition of thiazide‑type diuretics (e.g., metolazone) for patients who remain volume‑overloaded despite moderate‑ or high‑dose loop diuretics, as combination therapy raises the risk of electrolyte abnormalities. 2